Toronto, Ontario--(Newsfile Corp. - July 8, 2021) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce the completion and validation that its AcuVid™ COVID-19 Rapid Antigen Saliva Test successfully detected the highly contagious, fast moving COVID-19 Delta B.1.617.2 variant. The AcuVid™ / Delta variant study was completed at the Company's Brazilian clinical study partner's lab location at the Federal University of Minas Gerais.

Ever since the SARS-CoV-2 Novel Coronavirus became a global pandemic in 2020, new variants have emerged, and the scientific community has worked diligently and tirelessly to evaluate each strain and its impact on our health. The Delta B.1.617.2 variant has now become the dominant COVID-19 strain around the world; including the United States, United Kingdom, Europe, part of Africa and India. Out of an abundance of caution, the World Health Organization has urged fully vaccinated people to continue wearing masks due to this new variant strain.

The Delta variant is becoming the fastest moving, most dominant COVID-19 strain globally; on June 24^th Therma Bright and its partners announced and initiated the Delta variant study. The study focused on ensuring the Company's AcuVid™ COVID-19 Rapid Antigen Saliva Test would successfully perform and easily detect the ever-growing list of mutations from the original Wuhan SARS-CoV-2 Novel Coronavirus. To date, Therma Bright's AcuVid™ saliva test has successfully detected not only the original virus, but the P.1 and P.2 variants discovered in Brazil, the B.1.1.7 variant from the UK and now the highly-contagious Delta B.1.617.2 variant from India.

"We believe that the spread of the COVID-19 virus can be mitigated by early detection through serial testing of individuals," expressed Rob Fia, CEO of Therma Bright. "Many antigen test manufacturers believe their solutions will be able to detect these new, mutating variants. At Therma Bright, we have gone that extra mile to conduct the critical research to validate and ensure our AcuVid™ COVID-19 Rapid Antigen Saliva Test does indeed successfully detect not only the original COVID-19 virus, but all major variants, including this fast moving and most contagious Delta strain."

Therma Bright is not making any express or implied claims that its test product has the ability to eliminate or cure COVID-19 or the SARS-CoV-2 virus.

Sources: Delta variant news coverage as becoming the dominant COVID-19 variant in US, UK, Europe, India and Africa

• USA: https://www.cnbc.com/2021/07/07/cdc-data-shows-delta-is-now-the-dominant-covid-variant-in-the-us.html
• UK: https://www.cbsnews.com/news/delta-variant-covid-uk-warning-hope/
• Europe/Africa: https://www.cidrap.umn.edu/news-perspective/2021/07/africa-europe-feel-impact-covid-19-delta-variant-spread
• India: https://www.nature.com/articles/d41586-021-01274-7

About Therma Bright Inc.

Therma Bright, developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test, is a progressive medical diagnostic and device technology company focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. The Company's initial breakthrough proprietary technology delivers effective, non-invasive and pain-free skincare. Therma Bright received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation of a variety of insect bites or stings. The Company received clearance for the above claims from the US FDA in 1997. Therma Bright Inc. trades on the TSXV (TSXV: THRM) (OTC Pink: THRBF) (FSE: JNX). Visit: www.thermabright.com.

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Follow us on Twitter

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as development and commercialization of a rapid COVID-19 viral assay and related instrumentation. as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release is not an offer of the securities for sale in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/89744